Ionis Pharmaceuticals, Inc.

Informe acción NasdaqGS:IONS

Capitalización de mercado: US$6.1b

Ionis Pharmaceuticals Dirección

Dirección controles de criterios 2/4

El CEO de Ionis Pharmaceuticals es Brett Monia , nombrado en Jan 2020, tiene una permanencia de 4.83 años. compensación anual total es $12.50M, compuesta por 7.7% salario y 92.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.11% de las acciones de la empresa, por valor de $6.74M. La antigüedad media del equipo directivo y de la junta directiva es de 4.8 años y 8.5 años, respectivamente.

Información clave

Brett Monia

Chief Executive Officer (CEO)

US$12.5m

Compensación total

Porcentaje del salario del CEO7.7%
Permanencia del CEO4.8yrs
Participación del CEO0.1%
Permanencia media de la dirección4.8yrs
Promedio de permanencia en la Junta Directiva8.5yrs

Actualizaciones recientes de la dirección

Recent updates

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Oct 23

There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Aug 24
There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

Aug 11

Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Jul 28
Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

May 28

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

May 09
Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Apr 14
Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Mar 18
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Feb 23

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Dec 28
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Dec 07
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Nov 16
A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Aug 03
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

May 05
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?

Jan 20
Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?

Ionis Pharmaceuticals Looks Good For The Long Term

Oct 19

Ionis plans for new manufacturing site in California to support pipeline

Oct 13

Ionis: 2 Drug Advancements With Potential Firsts

Aug 29

Ionis Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Ionis Pharmaceuticals (NASDAQ:IONS) Could Easily Take On More Debt

Aug 08
Ionis Pharmaceuticals (NASDAQ:IONS) Could Easily Take On More Debt

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Brett Monia en comparación con los beneficios de Ionis Pharmaceuticals?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2024n/an/a

-US$366m

Mar 31 2024n/an/a

-US$385m

Dec 31 2023US$13mUS$961k

-US$366m

Sep 30 2023n/an/a

-US$409m

Jun 30 2023n/an/a

-US$309m

Mar 31 2023n/an/a

-US$329m

Dec 31 2022US$7mUS$825k

-US$270m

Sep 30 2022n/an/a

US$7m

Jun 30 2022n/an/a

-US$28m

Mar 31 2022n/an/a

-US$4m

Dec 31 2021US$13mUS$800k

-US$29m

Sep 30 2021n/an/a

-US$608m

Jun 30 2021n/an/a

-US$550m

Mar 31 2021n/an/a

-US$495m

Dec 31 2020US$11mUS$700k

-US$444m

Sep 30 2020n/an/a

US$94m

Jun 30 2020n/an/a

US$145m

Mar 31 2020n/an/a

US$169m

Dec 31 2019US$7mUS$528k

US$281m

Sep 30 2019n/an/a

US$433m

Jun 30 2019n/an/a

US$402m

Mar 31 2019n/an/a

US$366m

Dec 31 2018US$4mUS$508k

US$277m

Sep 30 2018n/an/a

-US$41m

Jun 30 2018n/an/a

-US$38m

Mar 31 2018n/an/a

US$9m

Dec 31 2017US$2mUS$443k

US$19m

Compensación vs. Mercado: La compensación total de Brett($USD12.50M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD8.06M).

Compensación vs. Ingresos: La compensación de Brett ha aumentado mientras la empresa no es rentable.


CEO

Brett Monia (63 yo)

4.8yrs

Permanencia

US$12,500,023

Compensación

Dr. Brett P. Monia, Ph.D. is a Founder of Ionis Pharmaceuticals, Inc. in 1989 and has been Chief Executive Officer since January 2020. He has extensive experience across a range of therapeutic areas, inclu...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Brett Monia
Founder4.8yrsUS$12.50m0.11%
$ 6.7m
Elizabeth Hougen
Executive VP of Finance & CFO11.8yrsUS$2.89m0.059%
$ 3.6m
B. Parshall
Director6.8yrsUS$538.04k0.055%
$ 3.4m
Richard Geary
Executive VP & Chief Development Officer16.3yrsUS$2.56m0.054%
$ 3.3m
Eric Swayze
Executive Vice President of Research4.8yrsUS$2.56m0.022%
$ 1.4m
Darren Gonzales
Chief Accounting Officer & Senior VP4.8yrssin datossin datos
C. Bennett
Executive VP & Chief Scientific Officer4.8yrsUS$958.87k0.051%
$ 3.1m
D. Walke
Senior Vice President of Investor Relationsno datasin datossin datos
Patrick O'Neil
Executive VP11.8yrsUS$3.92m0.031%
$ 1.9m
Hayley Soffer
Vice President of Corporate Communicationsless than a yearsin datossin datos
Shannon Devers
Senior Vice President of Human Resources4.8yrssin datos0.0050%
$ 306.5k
Stanley Crooke
Scientific Advisor3.4yrsUS$2.28msin datos

4.8yrs

Permanencia media

64.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de IONS se considera experimentado (4.8 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Brett Monia
Founder5.7yrsUS$12.50m0.11%
$ 6.7m
B. Parshall
Director24.2yrsUS$538.04k0.055%
$ 3.4m
Joan Herman
Independent Director5.4yrsUS$540.04k0.027%
$ 1.6m
Joseph Klein
Independent Director18.9yrsUS$542.04k0.010%
$ 637.4k
Joseph Wender
Lead Independent Director30.8yrsUS$598.04k0.084%
$ 5.1m
Michael Hayden
Independent Director6.2yrsUS$528.04k0.020%
$ 1.2m
Spencer Berthelsen
Independent Director22.5yrsUS$548.04k0.097%
$ 5.9m
Joseph Loscalzo
Independent Chairman of the Board10.8yrsUS$568.04k0.029%
$ 1.8m
Allene Diaz
Independent Director3.4yrsUS$530.04k0.010%
$ 609.3k
Michael Yang
Independent Directorless than a yearUS$363.05ksin datos

8.5yrs

Permanencia media

70yo

Promedio de edad

Junta con experiencia: La junta directiva de IONS se considera experimentada (8.5 años de antigüedad promedio).